Diarrhea News and Research

Latest Diarrhea News and Research

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

CDH first hospital in New England to use Xenex PX-UV disinfection system

Cooley Dickinson Hospital (CDH) today announced it is the first hospital in New England to use the Xenex PX-UV disinfection system to disinfect its patient and operating rooms.

2 Feb 2011

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO Pharmaceuticals, Inc. today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

1 Feb 2011

Silicon dioxide coated rust nanoparticles to fight cervical cancer

The next big thing in medical diagnostics could be minutes particles of rust, iron oxide, coated with the material from which sand is formed, silicon dioxide. These magnetic nanoparticles, a mere 29 to 230 nanometers across, can be used to trap antibodies to the virus that causes cervical cancer and to the bacteria that causes potentially lethal diarrhea.

1 Feb 2011

U.K., Gates Foundation announce extra funding for global polio eradication as WEF wraps up

U.K. Prime Minister David Cameron and Bill Gates, co-chair of the Bill & Melinda Gates Foundation, on Friday at the World Economic Forum (WEF) in Davos, Switzerland, announced "extra financing for polio eradication, easing a shortfall in funding that hinders a global effort to stop the crippling virus," Bloomberg reports.

1 Feb 2011

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).

1 Feb 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

Improper food handling can lead to gastrointestinal illness in children

In the confined space of a classroom, gastrointestinal illnesses can spread quickly, causing sufferers many painful and uncomfortable symptoms. But what is to blame for a school-based outbreak? In most cases, improper food handling is the culprit, says a Ryerson University public health expert.

28 Jan 2011

CSL Behring receives marketing approval for HAE drug Berinert in Israel

CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.

28 Jan 2011

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib in non-small cell lung cancer at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

28 Jan 2011

Lancet series examines health issues facing populations in Southeast Asia

"Southeast Asia's 600 million people are facing a raft of new health challenges as the disaster-prone region undergoes some of the world's fastest social change," according to a series of papers and commentary pieces, published Tuesday in the Lancet, Agence France-Presse reports (O'Brien, 1/25).

27 Jan 2011

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.

25 Jan 2011

Wrigley launches school-based program to improve health, nutrition in school-age children

The Wm. Wrigley Jr. Company Foundation today announced the launch of a two-year, $3 million school health partnership with Save the Children. The initiative will be activated in six countries across the world, aimed at improving the health and nutrition of more than 273,000 school-age children in disadvantaged communities.

25 Jan 2011

PediatRx announces first-ever revenues and successful launch of GRANISOL

PediatRx Inc.is pleased to provide an update on activities for the fiscal third quarter. Among its achievements, the hospital specialty pharmaceutical company reported its first-ever revenues and successfully launched GRANISOL™, the company's first commercial entry.

24 Jan 2011

Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation

Furiex Pharmaceuticals, Inc. today announced that its novel diarrhea-predominant irritable bowel syndrome treatment called MuDelta, now in Phase II clinical trials, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

24 Jan 2011

FDA accepts Optimer's fidaxomicin NDA for filing

Optimer Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI.

24 Jan 2011

Diarrhea News and Research

Latest Diarrhea News and Research

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

CDH first hospital in New England to use Xenex PX-UV disinfection system

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

Silicon dioxide coated rust nanoparticles to fight cervical cancer

U.K., Gates Foundation announce extra funding for global polio eradication as WEF wraps up

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

Baxter launches OLIMEL emulsion for parenteral nutrition

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

Improper food handling can lead to gastrointestinal illness in children

CSL Behring receives marketing approval for HAE drug Berinert in Israel

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Lancet series examines health issues facing populations in Southeast Asia

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Wrigley launches school-based program to improve health, nutrition in school-age children

PediatRx announces first-ever revenues and successful launch of GRANISOL

Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation

FDA accepts Optimer's fidaxomicin NDA for filing

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in